No Data
No Data
Arcutis Biotherapeutics | 10-Q/A: Quarterly report (Amendment)
Express News | Arcutis Biotherapeutics Inc - Zoryve Foam Demonstrates Favorable Safety Profile
Express News | Arcutis Biotherapeutics Inc - Zoryve Foam Significantly Improved Psoriasis in Trials
Express News | Arcutis Submits Supplemental New Drug Application for Zoryve® (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Express News | Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $19 From $18
Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL
No Data
Benjamin’s :![boom 💥](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f4a5.png)